LEXEO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.46 USD | -0.13% |
|
+11.62% | +15.20% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 357.6 | 509.3 | - | - |
| Enterprise Value (EV) 1 | 236.1 | 284.4 | 388.9 | 509.3 |
| P/E ratio | -1.08 x | -6.18 x | -6.32 x | -7.13 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 453 x | 170 x |
| EV / Revenue | - | - | 346 x | 170 x |
| EV / EBITDA | -3,459,997 x | - | - | - |
| EV / FCF | -3.96 x | -3.65 x | -4.26 x | -4.39 x |
| FCF Yield | -25.2% | -27.4% | -23.5% | -22.8% |
| Price to Book | 3.15 x | 3.48 x | 2.84 x | 4.88 x |
| Nbr of stocks (in thousands) | 26,646 | 32,945 | - | - |
| Reference price 2 | 13.42 | 15.46 | 15.46 | 15.46 |
| Announcement Date | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1.125 | 3 |
| EBITDA | - | -68.24 | - | - | - |
| EBIT 1 | - | -68.51 | -92.54 | -104.7 | -136.4 |
| Operating Margin | - | - | - | -9,310.64% | -4,546.47% |
| Earnings before Tax (EBT) 1 | - | -66.39 | -76.49 | -91.53 | -79.66 |
| Net income 1 | -59.28 | -66.39 | -74.59 | -86.04 | -79.27 |
| Net margin | - | - | - | -7,647.69% | -2,642.22% |
| EPS 2 | -36.34 | -12.40 | -2.503 | -2.446 | -2.167 |
| Free Cash Flow 1 | - | -59.61 | -77.93 | -91.38 | -116 |
| FCF margin | - | - | - | -8,122.22% | -3,865% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 29/09/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | -20.12 | - | -23.22 | - | - | - | - | - |
| EBIT 1 | -20.27 | -14.97 | -23.29 | -26 | -28 | -30 | -33 | -36 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -20.11 | -14.19 | -21.68 | -22 | -24 | -26 | - | - |
| Net income 1 | -20.11 | -14.19 | -21.68 | -18.18 | -18.18 | -14.67 | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -1.220 | - | -0.7700 | -0.5991 | -0.5657 | -0.5124 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/23 | 11/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 121 | 225 | 120 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -59.6 | -77.9 | -91.4 | -116 |
| ROE (net income / shareholders' equity) | - | -58.5% | -61.9% | -46.2% | -47.2% |
| ROA (Net income/ Total Assets) | - | -56.1% | -51% | -39.9% | -40.8% |
| Assets 1 | - | 118.4 | 146.1 | 215.5 | 194.5 |
| Book Value Per Share 2 | - | 4.260 | 4.450 | 5.450 | 3.170 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.12 | 2.08 | 2.3 | 2.43 |
| Capex / Sales | - | - | - | 204.44% | 81.11% |
| Announcement Date | 29/09/23 | 11/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.46
USD
Average target price
21.4
USD
Spread / Average Target
+38.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.20% | 509M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- LXEO Stock
- Financials Lexeo Therapeutics, Inc.
